FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093667178> ?p ?o ?g. }

• W2093667178 endingPage "02" @default.
• W2093667178 startingPage "P1" @default.
• W2093667178 abstract "Abstract Background: HER2 overexpression is associated with unfavorable prognosis and is reported in 18–25% of breast cancers (BC). HER2 testing is often performed using immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH). Because of the significant benefit of HER2−directed therapies, it is critical to accurately identify women whose tumors are HER2+. Reports have noted discordance between HER2+ test results from local vs. large reference labs in patients with HER2+ BC evaluated for trastuzumab-based clinical studies. There are little published data on central testing of BC found to be negative locally. Patients and Methods: VIRGO is an observational cohort of N=1,287 women with primarily HER2−negative metastatic BC. An optional tissue collection substudy was conducted, and 776 patient samples were received and centrally retested. Central testing was performed at 2 reference labs and tumors were deemed HER2+ if IHC 3+ and/or FISH positive (HER2:CEP17 ratio ≥2.0). Tumors with unknown/missing local HER2 status (n=68) were excluded from primary analyses. Number of patients potentially affected based on BC incidences from the American Cancer Society (ACS) 2011 estimates and the World Health Organization (WHO) 2008 report were calculated. Testing on the remainder of the HER2−negative cohort is in process. Results: Central retesting has been performed on tumor samples from n=373 patients to date: HER2−negative locally evaluable tumors (n=301), n=4 HER2−negative locally with no evaluable tumor, and HER2 unknown (n=68). A total of 301 unique patient samples were included in the primary analysis. Of these, 15 (4.98% [95% CI (2.7%, 7.9%)] were found to be HER2+ by central testing (Table). Based on sensitivity analyses assuming all 68 tumors with unknown HER2 status to be negative locally, 4.07%(15 /369) would be centrally HER2+. Of the 15 HER2+ tumors, 4 tumors tested positive centrally by both IHC and FISH; 6 IHC positive/FISH negative; and 5 FISH positive/IHC negative. 14/15 tumors were tested locally by only one testing methodology, and 11/15 were determined to be HER2+ centrally based on the testing methodology not performed locally. Investigators for all 15 patients have been notified of central HER2 testing results. Conclusion: Based on ACS estimates of 232,620 new cases of invasive BC diagnosed in the US in 2011 (assuming 80% testing HER2−negative); a discordance rate of 4–5% equates to 7,444 - 9,305 patients’ tumors diagnosed as HER2+ by central testing. Based on WHO global BC incidence estimates, 44,274 - 55,342 patients could be impacted worldwide as reported in this study. Inaccurate HER2 testing has significant clinical impact, both in denying appropriate treatment or leading to inappropriate use of HER2−targeted therapies. This study suggests testing by both IHC and FISH may be of benefit to accurately identify HER2 status, consistent with the Herceptin® USPI. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-07-02." @default.
• W2093667178 created "2016-06-24" @default.
• W2093667178 creator A5003097936 @default.
• W2093667178 creator A5007414140 @default.
• W2093667178 creator A5019132733 @default.
• W2093667178 creator A5030502460 @default.
• W2093667178 creator A5038303596 @default.
• W2093667178 creator A5049358292 @default.
• W2093667178 creator A5058128666 @default.
• W2093667178 creator A5064959473 @default.
• W2093667178 creator A5067203408 @default.
• W2093667178 creator A5072015843 @default.
• W2093667178 creator A5072308451 @default.
• W2093667178 creator A5079737792 @default.
• W2093667178 creator A5090926486 @default.
• W2093667178 date "2011-12-01" @default.
• W2093667178 modified "2023-10-06" @default.
• W2093667178 title "P1-07-02: Discordance between Central and Local Laboratory HER2 Testing from a Large HER2−Negative Population in VIRGO, a Metastatic Breast Cancer Registry." @default.
• W2093667178 doi "https://doi.org/10.1158/0008-5472.sabcs11-p1-07-02" @default.
• W2093667178 hasPublicationYear "2011" @default.
• W2093667178 type Work @default.
• W2093667178 sameAs 2093667178 @default.
• W2093667178 citedByCount "5" @default.
• W2093667178 countsByYear W20936671782012 @default.
• W2093667178 countsByYear W20936671782017 @default.
• W2093667178 countsByYear W20936671782022 @default.
• W2093667178 crossrefType "journal-article" @default.
• W2093667178 hasAuthorship W2093667178A5003097936 @default.
• W2093667178 hasAuthorship W2093667178A5007414140 @default.
• W2093667178 hasAuthorship W2093667178A5019132733 @default.
• W2093667178 hasAuthorship W2093667178A5030502460 @default.
• W2093667178 hasAuthorship W2093667178A5038303596 @default.
• W2093667178 hasAuthorship W2093667178A5049358292 @default.
• W2093667178 hasAuthorship W2093667178A5058128666 @default.
• W2093667178 hasAuthorship W2093667178A5064959473 @default.
• W2093667178 hasAuthorship W2093667178A5067203408 @default.
• W2093667178 hasAuthorship W2093667178A5072015843 @default.
• W2093667178 hasAuthorship W2093667178A5072308451 @default.
• W2093667178 hasAuthorship W2093667178A5079737792 @default.
• W2093667178 hasAuthorship W2093667178A5090926486 @default.
• W2093667178 hasConcept C121608353 @default.
• W2093667178 hasConcept C126322002 @default.
• W2093667178 hasConcept C143998085 @default.
• W2093667178 hasConcept C2775930923 @default.
• W2093667178 hasConcept C2778527826 @default.
• W2093667178 hasConcept C2779786085 @default.
• W2093667178 hasConcept C2908647359 @default.
• W2093667178 hasConcept C29456083 @default.
• W2093667178 hasConcept C530470458 @default.
• W2093667178 hasConcept C71924100 @default.
• W2093667178 hasConcept C72563966 @default.
• W2093667178 hasConcept C99454951 @default.
• W2093667178 hasConceptScore W2093667178C121608353 @default.
• W2093667178 hasConceptScore W2093667178C126322002 @default.
• W2093667178 hasConceptScore W2093667178C143998085 @default.
• W2093667178 hasConceptScore W2093667178C2775930923 @default.
• W2093667178 hasConceptScore W2093667178C2778527826 @default.
• W2093667178 hasConceptScore W2093667178C2779786085 @default.
• W2093667178 hasConceptScore W2093667178C2908647359 @default.
• W2093667178 hasConceptScore W2093667178C29456083 @default.
• W2093667178 hasConceptScore W2093667178C530470458 @default.
• W2093667178 hasConceptScore W2093667178C71924100 @default.
• W2093667178 hasConceptScore W2093667178C72563966 @default.
• W2093667178 hasConceptScore W2093667178C99454951 @default.
• W2093667178 hasIssue "24_Supplement" @default.
• W2093667178 hasLocation W20936671781 @default.
• W2093667178 hasOpenAccess W2093667178 @default.
• W2093667178 hasPrimaryLocation W20936671781 @default.
• W2093667178 hasRelatedWork W1722328147 @default.
• W2093667178 hasRelatedWork W188069312 @default.
• W2093667178 hasRelatedWork W2001196910 @default.
• W2093667178 hasRelatedWork W2130521606 @default.
• W2093667178 hasRelatedWork W2158916914 @default.
• W2093667178 hasRelatedWork W2934076975 @default.
• W2093667178 hasRelatedWork W3112926233 @default.
• W2093667178 hasRelatedWork W4253790588 @default.
• W2093667178 hasRelatedWork W4383618614 @default.
• W2093667178 hasRelatedWork W2342209702 @default.
• W2093667178 hasVolume "71" @default.
• W2093667178 isParatext "false" @default.
• W2093667178 isRetracted "false" @default.
• W2093667178 magId "2093667178" @default.
• W2093667178 workType "article" @default.